

---

Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A, Maris JM, Hogarty M. Deregulated WNT/beta-catenin program in high-risk neuroblastomas without MYCN amplification. *Oncogene*; 27(10):1478-88, 2008.

Raney B, Anderson J, Breneman J, Donaldson S, Huh W, Maurer HM, Michalski J, Qualman S, Ullrich F, Wharam MD, Meyer W. Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on intergroup rhabdomyosarcoma study group (IRSG) protocols -II through -IV, 1978-1997; a Report from the Children's Oncology Group. *Pediatr Blood Cancer*; :, 2008.

Su N, Pan YX, Zhou M, Harvey RC, Hunger S, Kilberg MS. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. *Pediatr Blood Cancer*; 50(2):274-9, 2008.

Meyers P, Schwartz C, Krailo M, Bernstein M, Betcher DL, Conrad EU, Ferguson WS, Gebhardt M, Goorin A, Harris M, Healey J, Kleinerman E, Link M, Nadel H, Nieder M, Sato J, Siegal GP, Weiner M, Wells RJ, Womer R, Grier H. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: A report from the Children's Oncology Group. *J Clin Oncol*; :633-638, 2008.

Schneiderman J, London W, Brodeur GM, Castleberry RP, Look AT, Cohn S. Clinical Significance of MYCN Amplification and Ploidy in "Favorable" Stage Neuroblastoma. *J Clin Oncol*; 26(6):913-8, 2008.